ABSTRACT: Coronary artery disease is prevalent in different causes of out-of-hospital cardiac arrest (OHCA), especially in individuals presenting with shockable rhythms of ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT). The purpose of this report is to review the known prevalence and potential importance of coronary artery disease in patients with OHCA and to describe the emerging paradigm of treatment with advanced perfusion/reperfusion techniques and their potential benefits on the basis of available evidence. Although randomized clinical trials are planned or ongoing, current scientific evidence rests principally on observational case series with their potential confounding selection bias. Among patients resuscitated from VF/pVT OHCA with ST-segment elevation on their postresuscitation ECG, the prevalence of coronary artery disease has been shown to be 70% to 85%. More than 90% of these patients have had successful percutaneous coronary intervention. Conversely, among patients resuscitated from VF/pVT OHCA without ST-segment elevation on their postresuscitation ECG, the prevalence of coronary artery disease has been shown to be 25% to 50%. For these patients, early access to the cardiac catheterization laboratory is associated with a 10% to 15% absolute higher functionally favorable survival rate compared with more conservative approaches of late or no access to the cardiac catheterization laboratory. In patients with VF/pVT OHCA refractory to standard treatment, a new treatment paradigm is also emerging that uses venoarterial extracorporeal membrane oxygenation to facilitate return of normal perfusion and to support further resuscitation efforts, including coronary angiography and percutaneous coronary intervention. The burden of coronary artery disease is high in this patient population, presumably causative in most patients. The strategy of venoarterial extracorporeal membrane oxygenation, coronary angiography, and percutaneous coronary intervention has resulted in functionally favorable survival rates ranging from 9% to 45% in observational studies in this patient population. Patients with VF/pVT should be considered at the highest severity in the continuum of acute coronary syndromes. These patients have a significant burden of coronary artery disease and acute coronary thrombotic events. Evidence from randomized trials will further define optimal clinical practice.
A ccording to the 2015 Institute of Medicine report Strategies to Improve Cardiac Arrest Survival: A Time to Act, ≈395 000 people suffer an out-of-hospital cardiac arrest (OHCA) each year in the United States. 1 The survival rate is 6% to 10%, resulting in >350 000 deaths per year, making sudden cardiac arrest virtually synonymous with sudden cardiac death. 1, 2 Over the past 20 years, a significant body of evidence has emerged highlighting the importance of significant coronary artery disease (CAD; unless otherwise specified, hereafter defined as 1 narrowing of coronary luminal diameter of >70%) in patients presenting with ventricular fibrillation (VF)/pulseless ventricular tachycardia (pVT) and OHCA. The accumulated evidence for the presence of significant CAD in patients with VF/ pVT cardiac arrest has introduced significant scientific questions about the role and timing of diagnostic and interventional procedures to identify and reverse this potential cause of cardiac arrest.
Furthermore, a novel notion has been forming in the international resuscitation community suggesting that early access to the cardiac catheterization laboratory (CCL) serves 3 roles in this group of patients: (1) It provides a more informed diagnosis (of CAD or its absence), which can better guide future therapy even in the absence of a percutaneous coronary intervention (PCI); (2) it allows immediate PCI, which improves hemodynamics and prognosis analogous to patients with acute coronary syndromes; and (3) it provides access to circulatory assist devices that can be used to support and stabilize patients beyond standard medical therapy. Therefore, access to the CCL has the potential to improve outcomes in these patients.
For many patients, the first presenting symptom of an acute coronary syndrome is sudden cardiac death. In a 1984 autopsy study, patients who died of ischemic heart disease within 6 hours after symptom onset were compared with control subjects who died of natural or unnatural noncardiac causes within 6 hours after symptom onset. Controls were matched to cases by age, sex, and socioeconomic status. Intraluminal thrombosis was observed in 93% of cases and 4% of controls. 3 In another 1988 case series of patients undergoing autopsy after unsuccessful field resuscitation, CAD was considered to be the cause of death in 78% of patients with a presenting rhythm of VF. 4 Although VF/pVT constitutes only 20% to 30% of all cardiac arrests, 60% to 80% of all cardiac arrest survivors with favorable neurological function present with VF/pVT ( Figure 1 ). In fact, compared with the other presenting rhythms (asystole and pulseless electrical activity [PEA] ), VF/pVT is associated with the highest survival and predictive factor for neurologically intact survival, with odds ratios (ORs) ranging from 5 to 15 or greater. [5] [6] [7] [8] Yet, despite having a more favorable prognosis than those with other rhythm causes of OHCA, only ≈25% to 30% of patients with OHCA caused by VF/pVT survive to hospital discharge with good neurological function. Thus, identifying more effective treatments for all rhythm causes of OHCA remains a high priority, particularly the role of acute coronary intervention. For that reason and given the potential implication of costs and resources that may be needed to provide access to the CCL for most patients with OHCA, we present the available evidence of the potential benefit of emergent CCL access and subsequent interventions in patients with OHCA on the basis of initial presentation with shockable and nonshockable rhythms and the presence of refractory cardiac arrest.
THE PRESENCE OF CAD IN PATIENTS WITH OHCA Shockable Rhythms: The Weighted Importance of Shockable Rhythms to Survival
In most medical conditions, identification and treatment of an underlying pathogenesis are a fundamental tenant of medical practice and provide improved outcomes. For patients with VF/pVT OHCA, CAD is the most common reversible underlying cause. 7, 9 Patients resuscitated from VF/pVT cardiac arrest have clinically significant coronary stenosis in 25% to 50% of cases. 3, [10] [11] [12] [13] [14] [15] [16] Fundamentally, patients who present with OHCA VF/pVT can be divided into 2 major categories: patients with return of spontaneous circulation (ROSC) and patients with refractory VF/pVT. Most survivors achieve ROSC in <15 minutes after cardiopulmonary resuscitation (CPR) and other life support interventions. After that, survival dramatically decreases. [17] [18] [19] We define refractory VF/pVT as that which remains either recurrent or incessant after >3 direct current shocks or after antiarrhythmic medications have been given. Usually, both of those interventions fall within a 15-minute window from the initiation of resuscitation after the 9-1-1 call.
Patients with ROSC can be further divided into those who have ST-segment elevation on their 12-lead ECG and those who do not. Thus, we can categorize the patients with VF/pVT into 3 major groups that also represent different severities of CAD and outcomes ( Figure 2 ):
1. Patients with sustained ROSC and without the presence of ST-segment elevation on the initial surface ECG have been shown to have significant CAD, with prevalence varying between 25% and 50% in different published cohorts. 16, 20 Acute coronary lesions were identified in 25% to 35% of cases.
Patients with sustained ROSC and ST-segment
elevation or new left bundle-branch block on the surface ECG have been shown to have significant CAD in 70% to 95% of cases, with acute coronary lesions in 70% to 80%. 16, 20 3. Patients with refractory VF/pVT have been shown to have significantly higher rates of CAD (75%-85%), often with greater severity, and a higher prevalence of multivessel disease and chronic total coronary occlusions compared with resuscitated patients. 7, [14] [15] [16] [21] [22] [23] [24] [25] [26] Acute coronary lesions were present in 60% to 65% of the patients who had CAD. 7, 23 The accumulated data suggest that VF/pVT as the presenting cardiac arrest rhythm is a strong predictor of acute coronary occlusion or stenosis, which may be amenable to timely PCI.
Nonshockable Rhythms
Nonshockable rhythms can be divided into asystole and PEA. The presence of CAD in this population is poorly defined. In mainly autopsy studies, these populations have shown lower rates of CAD compared with shockable rhythms, but meaningful comparisons are impossible because of inconsistent autopsy indications and permissions. 4, 23, 27 Furthermore, the outcomes for asystole and PEA are extremely poor, and there are no major published series of homogeneous populations that can inform a role for CAD in those rhythms, even in resuscitated patients, because access to the CCL is the exception. 23 With those limitations, the role of CAD in patients with nonshockable rhythms is unknown. 41 of 52%. A meta-analysis that included 3103 patients compared the outcomes of patients with OHCA according to early CAG versus early conservative strategy. 12 Early access to CAG with timely revascularization, when significant lesions were identified, was associated with a significant increase in the OR for survival and functionally favorable survival (pooled unadjusted OR for survival of 2.78 [95% CI, 1.89-4.10]; P<0.001; Figure 3 ). 42 It is important to recognize the potential for bias and confounding in observational studies, 28, 42 particularly with respect to the selection of comatose patients after OHCA for invasive treatments. In general, patients selected for early CAG after OHCA have generally had more favorable clinical and resuscitation parameters (eg, younger age, fewer comorbidities, more often witnessed having cardiac arrest, and recipients of bystander CPR) compared with patients in whom early CAG is not pursued. 42, 43 In addition, the indication or timing of early CAG was not specified in most studies, with use rates of CAG among studies that vary widely from 14% to 83%. 42 Since 2014, several large observational studies that have been published have used statistical techniques (covariate adjustment, propensity matching) or standardized treatment algorithms (Minnesota Resuscitation Consortium) to overcome some of these limitations of early studies (Table 1) . 11, 16, 20, 43 In a subgroup analysis of the Resuscitation Outcomes Consortium, 11 among 3981 patients who arrived at 151 43 In 2013, the Minnesota Resuscitation Consortium developed an organized approach for the management of patients resuscitated from OHCA caused by shockable rhythms that promoted early access (within 4 hours) to the CCL in the metro area of Minneapolis-St. Paul. 16 With a standardized protocol, 73% of patients underwent CAG within 4 hours after their OHCA. In this group, 151 (65%) had functionally favorable sur- Table 2 ). This was corroborated by the PROCAT registry (Parisian Region Out of Hospital Cardiac Arrest). 15 Dumas et al 15 reported that at least 1 coronary artery lesion was present in 128 of 134 patients (96%) with STEMI and in 176 of 301 patients (58%) with no ST-segment elevation. That prevalence was higher than in US registries because of the definition of significant CAD used: >70% stenosis in the United States and >50% in the French registry. 15, 16 Prevalence of CAD and Survival After CAG in Patients With Sustained ROSC After VF/pVT OHCA Without ST-Segment Elevation on the Initial 12-Lead ECG Whether access to the CCL for immediate CAG will result in improved functionally favorable survival in patients resuscitated from VF/pVT OHCA with no ST-segment elevation may depend on the prevalence of significant CAD. Kern et al 20 showed that 82 247 patients (33%) without ST-segment elevation undergoing CAG had a culprit lesion identified. Of those, 66 of 82 (81%) had successful PCI. 20 In comparison, patients in whom OHCA was accompanied by ST-segment elevation had higher rates of culprit lesions identified (154 of 192, 80%), and 93% had PCI. 20 Garcia et al 16 reported slightly different rates than Kern et al, 20 with a higher prevalence of CAD in patients with no ST-segment elevation (42% versus 33%) and lower rates in patients with STEMI (72% versus 80%; Table 2 ).
PATIENTS WITH SUSTAINED ROSC
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In a Parisian cohort of 695 patients without ST-segment elevation after OHCA, Dumas et al 14 reported that a culprit lesion was identified in 29% of the patients. Functionally favorable survival was significantly higher in patients who had CAD and were treated with PCI (43%) compared with patients with no culprit lesion (33%). In other studies encompassing 1145 patients with no ST-segment elevation and early access to CAG, the prevalence of CAD varied from 30% to 42%. 15, 16, 20 These cohorts of patients, representing CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; OHCA, out-of-hospital cardiac arrest; PCI, percutaneous coronary intervention; STE, ST-segment elevation; STEMI, ST-segment-elevation myocardial infarction; and VF/pVT, ventricular fibrillation/pulseless ventricular tachycardia.
Reprinted from Garcia et al. 16 Copyright © 2016, The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons AttributionNonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. different metropolitan areas and hospitals, demonstrate that the prevalence of disease in the population without ST-segment elevation is sufficiently high that early CAG has significant opportunity to identify culprit lesions. 15, 16, 20 Access to CAG and Effects on Survival in the United States Currently, anticipated survival to hospital discharge for patients resuscitated from VF/pVT OHCA with early access to CAG is similar regardless of the presence (60%) or absence (57%) of ST-segment elevation on ECG. In 2016, Millin et al 44 showed that patients presenting with STEMI after cardiac arrest are 13 times more likely to be taken urgently to the CCL than patients without STEMI (OR, 13.8 [95% CI, 4.9-39.0]). Most important, the cumulative data show that when taken to the CCL, as many as 32% of patients without ST-segment elevation had an acute culprit lesion requiring intervention compared with 72% of patients with STEMI (OR, 0.15
There are no randomized human studies to address whether early CAG improves functionally favorable survival from cardiac arrest. On the basis of observational studies that use large registries in the United States, early access to CAG appears to be associated with improved functionally favorable survival in patients with no ST-segment elevation. The published, absolute difference in survival between patients with no ST-segment elevation who receive early CAG and patients who do not is reported to be between 12% and 18% in the United States. 12, 16 There are no data to compare similar differences in patients with STEMI, given that most patients with STEMI undergo CAG.
The Minnesota Resuscitation Consortium Experience
In Minneapolis-St. Paul, a community that provides early access to the CCL after OHCA, patients between 18 and 75 years of age resuscitated from VF/pVT with no ST-segment elevation on ECG received early access to the CCL only two-thirds of the time (130 of 203, 64%). That observation underscores the point that even with consensus throughout an entire community, patients are still treated with discretion according to the receiving cardiologist's preference. Notably, in this setting, early access to the CCL was associated with improved functionally favorable survival after adjustment for a variety of demographic and resuscitation characteristics, including age, sex, race, year, location of arrest, bystander CPR, witnessed arrest, medical history of PCI, CABG, myocardial infarction, diabetes mellitus, hypertension, hyperlipidemia, and tobacco use (Table 3) . 16 
The Resuscitation Outcomes Consortium Prehospital Resuscitation Using an Impedance Valve and Early Versus Delayed Analysis Experience (Large North American Prehospital Clinical Trials Network)
Reporting from the PRIMED (Resuscitation Outcomes Consortium Prehospital Resuscitation Using an Impedance Valve and Early vs Delayed Analysis) database, Callaway et al 11 assessed the effect of early access to the CCL on functionally favorable survival. In one of the largest cardiac arrest studies to date in North America, only 19% (765 of 3981) of patients admitted to the hospital were investigated in the CCL, and of those, 705 (92%) had revascularization treatment. This observation demonstrates that most hospitals in the United States and Canada do not access the CCL on the basis of organized protocols but rather as a sporadic strategy that may incorporate clinical judgment, clinician bias, and resource availability. The data from this study were also consistent with many other case series showing that early access to CAG had a positive association with functionally favorable survival. 33, 34, 36 Early access to CAG had the strongest association with survival of any hospital-based intervention, including therapeutic hypothermia (adjusted OR, 1.87 [95% CI, 1.15-3.04] versus 1.42 [95% CI, 1.04-1.94], respectively).
International Cardiac Arrest Registry Experience
Similarly, Kern et al 20 reported the association between early CAG and clinically appropriate PCI on outcomes in 548 patients with no ST-segment elevation on ECG after OHCA who were enrolled in INTCAR (International Reprinted from Garcia et al. 16 Copyright © 2016, The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
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Cardiac Arrest Registry). Access to the CCL resulted in a survival benefit, as shown in Figure 4 .
Transport to PCI-Capable Centers for Early CAG
Given the observed potential benefits of early CAG and revascularization, studies have examined the strategies of emergency medical services (EMS) when transporting patients resuscitated from OHCA. Kragholm et al 45 assessed the effect of PCI centers and bypassing hospitals without PCI capabilities on survival by using the CARES data. Of 1507 patients with out-of-hospital ROSC, 1359 (90%) were transported to PCI centers, and 148 (10%) were transported to non-PCI hospitals. A total of 873 patients (60%) bypassed the nearest non-PCI hospital. Survival to hospital discharge was higher among those transported to PCI centers (34% versus 15%; adjusted OR, 2. 
Current Treatment Guidelines
The present consensus in the cardiology community on the need for early CAG to facilitate timely reperfusion applies only to those with ST-segment elevation. Current STEMI guidelines strongly recommend (Class I; Level of Evidence B-NR) early catheterization and reperfusion for postarrest patients manifesting ST-segment elevation, even if the patient remains comatose. 46, 47 However, there is no consensus about the value and necessity of early catheterization for resuscitated patients without ST-segment elevation despite nonrandomized data suggesting at least a modest prevalence of sig- nificant CAD in this subgroup. Some have advocated for randomized clinical trials before committing to this approach for all postarrest patients.
48-51
Randomized Controlled Trials
The potential biases and limitations from nonrandomized registry cohort studies are well described. Nine separate randomized clinical trials evaluating the potential survival benefit of early CAG after arrest in patients without ST-segment elevation are now planned or underway. Table 4 highlights the similarities and differences among the trials. [52] [53] [54] [55] [56] [57] [58] [59] These randomized clinical trials will collectively enroll >5000 patients over the next 5 years and will help define clinical practice in the future.
Nonshockable Rhythms and Early CAG
In past years, the epidemiology of OHCA has changed such that nonshockable rhythms (bradyasystole and PEA) are now more prevalent. 60 Nonshockable OHCA is more commonly associated with noncardiovascular disease and thus might be less expected to manifest remediable coronary lesions as its cause. 61 In addition, most reports of emergent cardiac catheterization have excluded patients with obvious noncardiac causes of OHCA. The discretionary selection of patients for cardiac catheterization after OHCA represents the greatest potential bias for all observational studies, regardless of the presenting arrest rhythm. Accordingly, the proportion of patients with OHCA caused by nonshockable arrhythmias has been small in these reports, representing ≈20% to 25% of the study populations. 62 Moreover, studies that have included a broader group of patients with OHCA undergoing cardiac catheterization have not separately described angiographic findings in the subgroup with nonshockable rhythms. Notably, a small observational report described a similar prevalence of obstructive CAD among resuscitated patients who were selected for catheterization, regardless of their presenting rhythm or postresuscitation ECG findings. The presence of obstructive coronary artery lesions ranged from ≈50% of patients across VF/pVT, asystole, and PEA subgroups in the absence of ST-segment elevation to >90% across subgroups when ST-segment elevation was present. 62 In the total study population, performance of cardiac catheterization was associated with improved survival after OHCA regardless of the presenting rhythm. These findings suggest that there is potential benefit from CAG in all patients who are resuscitated from OHCA and require further study.
Resuscitated Patients With OHCA and Coronary Revascularization in the CCL
When CAD is observed in patients resuscitated from OHCA, revascularization can be achieved safely with PCI in most cases, with 68% to 80% of patients receiving PCI in observational cohorts. 16, 20 In select patients, CABG may also be feasible. These observational studies demonstrate that patients who receive early coronary revascularization with PCI or CABG have a greater likelihood of survival, with ORs ranging from 2 to 5. 9, 11, 16 Although no single study has confirmed an association between the severity of CAD and the likelihood of survival, comparisons can be made between patients resuscitated in the field and patients with refractory VF/pVT treated with extracorporeal CPR (ECPR). Those with OHCA resuscitated in the field have multivessel CAD in 52% of cases 16 compared with 70% of cases for refractory VF/pVT arrest. 7 Rates of chronic total occlusions were similar between these cohorts, with 25% in resuscitated patients 20 and 33% in shock-refractory patients. 7 Spaulding et al 9 showed that in a cohort of 84 patients resuscitated from VF/pVT arrest, 60 (71%) had significant CAD and 40 (48%) had total coronary arterial occlusion. Angioplasty was attempted in 37 patients and was successful in 28. Overall survival to hospital discharge of these 80 patients was 38%. After multivariate analysis, a successful PCI was an independent predictor of survival (OR, 5.2 [95% CI, 1.1-24.5];
P=0.04).
Similarly, multiple case series have addressed the issue of procedural success and survival in resuscitated patients who subsequently present with STEMI. In 2004, Bendz et al 10 reported angiographic findings for 40 such consecutive patients. The most common culprit lesion was found in the left anterior descending artery (50%), and PCI was successful in 95% of the cases. Survival to hospital discharge was 72%, and all patients were alive 2 years later. Gorjup et al 31 reported similar results in 135 patients, with a PCI success rate of 87% and survival rate to hospital discharge of 67%. Overall, 53% had functionally favorable survival with CPC 1 or 2.
Data from the PROCAT registry, describing 435 patients who underwent CAG after OHCA, showed that at least 1 significant coronary artery lesion was present in 304 patients (70%). 15 Significant coronary lesions were identified in 96% of patients with STEMI and in 58% of patients with no ST-segment elevation. Coronary revascularization was an independent predictor of survival with an OR of 2.06 (95% CI, 1.15-3.66) regardless of ECG findings, as shown in Figure 5 .
Similarly, Garcia et al 16 demonstrated that revascularization (PCI/CABG) was independently associated with survival to hospital discharge and neurological recovery in 315 patients resuscitated from VF/pVT OHCA regardless of the presence or absence of ST-segment elevation (Table 5) .
In a similar French cohort of 695 patients without ST-segment elevation who underwent immediate CAG after OHCA, Dumas et al 14 reported that patients with an identifiable lesion and successful PCI had 43% functionally favorable survival compared with 33% of the patients who had no identifiable coronary cause of their arrest (P=0.03). Successful PCI was again an independent factor associated with good neurological survival. 14 Sideris et al 63 in 2014 reported the 5-year outcomes of a total of 300 comatose patients resuscitated predominantly from shockable rhythms who had CAG on admission. PCI was attempted in 91% of patients with significant lesions and was successful in 93% of attempts. Survival to discharge was 32%. After discharge, overall 5-year survival was 82%. Survival from admission to 5 years was 37.4±5.2% for patients with significant coronary lesions and 20.7±3.0% for those without (hazard ratio, 1.5 [95% CI, 1.12-2.0]; P=0.0067). This study suggests that survivors are expected to live 5 years, especially if they have had culprit lesions identified and PCI performed ( Figure 6A ). Geri et al 64 reported the longest follow-up for patients who received early CAG and showed that patients with CAD and PCI had higher short-and long-term survival up to 10 years compared with patients with no CAD ( Figure 6B ).
Multiple case series among resuscitated patients with OHCA who had ST-segment elevation on the initial ECG have consistently shown high procedural success with PCI and survival rates varying from 60% to 80%, with almost 90% of those patients surviving with favorable neurological outcomes (Table 6 ).
Complete revascularization also may be important to optimize patient outcomes 73 ; however, most patients resuscitated from cardiac arrest rarely receive multivessel PCI in the postarrest setting. 16, 74 Although data are limited, patients with ongoing cardiogenic shock after OHCA may also benefit from multivessel PCI. 74 
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Yannopoulos et al Cardiac Catheterization Laboratory in Out-of-Hospital Cardiac Arrest
The survival benefit associated with early revascularization after cardiac arrest may arise from 2 separate mechanisms. VF/pVT arrest is widely accepted to be of ischemic origin in most cases. Therefore, correcting the underlying ischemic pathogenesis may prevent future arrhythmias and rearrest, leading to improved survival. Second, revascularization would be expected to alleviate ischemia, which may promote cardiac recovery and prevent prolonged hemodynamic instability after cardiac arrest. This is the proposed mechanism by which revascularization is believed to improve survival in the setting of post-STEMI cardiogenic shock and led to recommendations for emergent revascularization in the setting of cardiogenic shock after an acute coronary event.
46, 75 The results of ongoing randomized trials may significantly inform these proposed mechanisms of benefit.
A summary of the factors associated with favorable outcomes after OHCA is shown in Table 7 .
Arrest or Rearrest in the CCL
Cardiac arrest is infrequent in the CCL itself. Historical reports estimate an incidence of ≈1%, 81,82 but such calculations are dependent on the severity of illness among the population undergoing CAG and intervention. In 2002, Anderson et al 82 reported >100 000 procedures from the American College of Cardiology-National Cardiovascular Data Registry and found an overall inhospital death rate of 1% to 5% among those with acute myocardial infarction and 6% if the catheterization was done urgently. Mehta et al 83 reported a VF/pVT incidence of 4% during PCI for acute myocardial infarction in the Primary Angioplasty in Myocardial Infarction trials. Today's CCL typically treats sicker patients with greater risk for serious complications, including cardiac arrest and death. More contemporary reports suggest that more than half (55%) of all PCIs are nonelective and that close to 20% are performed in clinically unstable patients. 84 The best estimate for current PCI-related in-hospital mortality, a surrogate for refractory cardiac arrest in the CCL, is 2% to 3%.
Manual chest compressions have been the primary technique for sustaining circulation during cardiac arrest. However, performing high-quality manual chest compressions in the CCL while attempting to recanalize an acutely occluded coronary artery can be challenging. Barriers include unsafe radiation to the chest compressor's hands, obstruction of the interventionist's view, frequent interruptions of chest compressions, and poor CPR quality.
One potential solution is to use a mechanical chest compressor. Mechanical chest compressions afford the Outcomes are based on the presence or absence of revascularization regardless of timing to cardiac catheterization laboratory access. CABG indicates coronary artery bypass graft; CPC, cerebral performance category; OR, odds ratio; and PCI, percutaneous coronary intervention.
*Adjusted for age, sex, race, history of PCI, CABG, myocardial infarction, diabetes mellitus, hypertension, congestive heart failure, hyperlipidemia, tobacco use, year, location of arrest, and bystander cardiopulmonary resuscitation witnessed arrest.
Reprinted from Garcia et al. 16 Copyright © 2016, The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. opportunity to initiate PCI or percutaneous circulatory support during ongoing CPR in patients with refractory cardiac arrest. Wagner et al 85, 86 reported 2 sequential case series of using mechanical CPR in the CCL among a combined total of 75 patients undergoing PCI. In the first of these studies, 88% (28 of 32) of the patients included in the mechanical chest compression cohort had their coronary or cardiac intervention performed during mechanical chest compressions with an 80% success rate. 86 In the second study, 86% (37 of 43) of patients with refractory cardiac arrest had their cardiac procedure or PCI successfully completed during ongoing mechanical CPR. 85 Overall, functionally favorable survival after refractory cardiac arrest was 25% (19 of 75) with 87% 1-year survival. Venturini et al 87 also reported their experience with 43 patients receiving CPR in the CCL. Nearly half (20 of 43) of these patients arrested in the CCL, whereas the other patients were brought to the CCL in refractory cardiac arrest with ongoing chest compressions. Of the 43 patients, 22 had venoarterial extracorporeal membrane oxygenation (VA-ECMO) initiated during mechanical chest compressions and were more likely to achieve ROSC than those not receiving VA-ECMO (100% versus 53%; P=0.003), demonstrating that initiation of such percutaneous extracorporeal life support was feasible and safe during mechanical chest compression-assisted resuscitation in the CCL. 87 Other therapeutic options for patients arresting in the CCL include percutaneously placed left ventricular assist devices. Large animal preclinical studies have shown that Impella can support systemic circulation without chest compressions during ischemic VF cardiac arrest but that intravascular volume loading is required. 88 Derwall et al, 89 using a porcine model of VF, found that this device can generate coronary perfusion pressures of 20 mm Hg, twice that of manual chest compressions. Compared with chest compressions alone, this increased hemodynamic support translated into a significant survival advantage at 24 hours (2 of 10 versus 9 of /10; P=0.003) in animals. 63 Copyright © 2014, SAGE Publications, Ltd. Reprinted by Permission of SAGE Publications, Ltd. B, Up to 10 years of follow-up for patients who gained access to the cardiac catheterization laboratory after resuscitated OHCA. PCI indicates percutaneous coronary intervention. Reprinted from Geri et al. 64 Copyright © 2015, American Heart Association, Inc.
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Percutaneous VA-ECMO has been used for refractory cardiac arrest in the CCL. Case series and reports have documented successful resuscitation attempts and left ventricular support with such technology after standard therapies have failed. 90, 91 This approach requires a multidisciplinary team and careful selection of appropriate candidates.
Today, mechanical chest compression devices and mechanical circulatory support devices are most commonly used in tandem, often sequentially. The "2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care" included treatment recommendations for cardiac arrest in the CCL, indicating that mechanical piston devices may be considered in specific settings in which the delivery of high-quality manual compressions may be challenging or dangerous for the provider (Class IIb; Level of Evidence C-EO). It also recommended providing chest compressions to patients in cardiac arrest during PCI and that it may be reasonable to use VA-ECMO as a rescue treatment when initial therapy is failing for cardiac arrest that occurs during PCI (Class IIb; Level of Evidence C-LD). 92, 93 Because feasibility and preliminary efficacy have now been demonstrated, these approaches are becoming more commonly applied in the CCL.
Refractory OHCA and the Role of the CCL Definition of Refractory VF/pVT
Advanced perfusion/reperfusion strategies using early EMS transport and initiation of ECMO, followed by CAG and PCI when needed, have been shown to result in a 43% functionally intact survival rate for patients with out-of-hospital refractory VF/pVT. 7 The definition of refractory VF/pVT can be chosen as a point along a theoretical continuum of failed response to standard care. Physicians have historically chosen the point of administration of initial antiarrhythmic as the point of labeling the VF as refractory. As the emergency response strategies evolve, different definitions may become prominent, and others may become obsolete. Along the time continuum of resuscitation efforts, interventions may be applied either too early or too late. For example, implementing a novel strategy too late along this continuum may not offer benefit because the patient is already too severely compromised. If it occurs too early, expensive resources may be mobilized unnecessarily. For these reasons, most of the investigations currently involving patients with refractory cardiac arrest choose a decision point, whether time or procedure based (eg, number of shocks), for optimal implementation. Common US EMS-based definitions suggest either 15 to 20 minutes of unsuccessful standard resuscitation or 3 unsuccessful shocks. 22, 94 We use this definition of refractory VF/pVT throughout this review.
CAD and Refractory VF/pVT Cardiac Arrest
Published data with VA-ECMO-supported angiographic evaluation in patients with refractory VF/pVT OHCA establish that there is a high burden of CAD in this population. 7, 23 The prevalence of complex CAD, combined with the relatively high survival rates in selected patients undergoing revascularization, supports the contention that the severity of underlying coronary artery pathology may be causally associated with the inability of standard resuscitation efforts to achieve ROSC in the majority of patients (Figure 7 ). 
VA-ECMO-Facilitated CAG/Angioplasty
Efforts to treat patients with refractory cardiac arrest have led to the use of ECMO to facilitate return Presenting rhythm was ventricular fibrillation/pulseless ventricular tachycardia in >95% of the cases. CAG indicates coronary angiography; NA, not available; OHCA, out-of-hospital cardiac arrest; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction. CAG indicates coronary angiography; CPR, cardiopulmonary resuscitation; OHCA, out-of-hospital cardiac arrest; OR, odds ratio; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction.
of normal perfusion and to support further resuscitation efforts, including CAG and PCI. Multiple cohorts have shown that such an approach is feasible in selected patients. Because time to initiation of ECPR is a critical predictor of survival, 2 major approaches to limit time to ECPR have been implemented. The first approach uses rapid EMS mobilization and transportation to the closest highly equipped emergency department or CCL, used in Asia, Australia, Canada, and the United States. The second approach mobilizes ECMOequipped emergency response units to the field with initiation of ECMO undertaken at the site of the arrest, used in Paris, France.
VA-ECMO for Refractory VF/pVT OHCA: Survival and Favorable Neurological Outcomes
Among 2885 adults in the 2016 Extracorporeal Life Support Organization registry database, survival to discharge after ECPR for cardiac arrest that was refractory to conventional resuscitation was 29%. 95 Such outcomes have varied widely in other published studies, principally drawn from non-US cohorts, mainly in Asia. 24, 25, [96] [97] [98] [99] Several studies of patients unresponsive to standard resuscitation who received VA-ECMO (and PCI when indicated) found worse outcomes with OHCA versus in-hospital cardiac arrest (IHCA). Kagawa et al 96 analyzed data for 86 patients with OHCA or IHCA unresponsive to CPR who received VA-ECMO (and PCI when indicated). Survival to day 30 was 29% overall, 17% (7 of 42) for OHCA versus 41% (18 of minutes; P=0.002) but also a higher rate of intra-arrest PCI (88% versus 70%; P=0.04). Wang et al 24 retrospectively described a cohort of 230 patients who had received VA-ECMO over a study period of 5 years (31 patients with OHCA and 199 with IHCA). No significant differences were observed between OHCA and IHCA in rate of survival to hospital discharge (39% versus 31%; P>0.05) or functionally favorable survival (26% versus 25%; P>0.05). As in the former study, the duration of ischemia (from collapse to VA-ECMO) was a strong predictor for survival. The authors attributed the high survival rate in patients with OHCA compared with previous studies 96, 97, 100, 101 to a well-organized and rapid-response EMS system, efficiency in handling patient transportation and resuscitation, and an equipped cart in the emergency department rather than in the intensive care unit, which shortened the duration of ischemia. 24 In Australia, Stub et al 21 treated 26 patients with refractory prolonged cardiac arrest with the CHEER protocol (mechanical CPR, hypothermia, ECMO, and early reperfusion) during a period of 32 months. Of 15 patients with IHCA, all had ROSC with VA-ECMO, and 
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9 (60%) survived. In 11 patients with OHCA (all with VF), ROSC was achieved in 2 patients before VA-ECMO was initiated and in 8 of 9 patients placed on VA-EC-MO. A total of 5 patients (45%) with OHCA survived, including 3 of 9 patients who were placed on VA-EC-MO. Avalli et al 100 reported their experience with VA-ECMO support in patients with refractory cardiac arrest (IHCA, n=24; OHCA, n=18). Survival to discharge from intensive care was 46% (11 of 24) for IHCA and 6% (1 of 18) for OHCA (P<0.05). At 6 months, survival rates with good neurological outcomes were 38% (9 of 24) for IHCA and 6% (1 of 18) for OHCA. Haneya et al 101 analyzed a total of 85 consecutive adult patients with refractory cardiac arrest treated with VA-ECMO. Thirtyday survival was 42% (25 of 59) in patients with IHCA and 15% (4 of 26) in patients with OHCA (P<0.02). Duration of CPR, as a possible surrogate for ischemic time, was an independent risk factor for mortality. In the United States, Johnson et al 102 reported 26 cases of people with cardiac arrest who received VA-ECMO (and reperfusion when indicated) over a 7-year period, of whom 11 (42%) presented with VF/pVT. Of 15 patients with OHCA, 1 patient (7%) who presented with VF/pVT survived to discharge and made a full neurological recovery. Survival to discharge was 27% (3 of 11) for IHCA.
In South Korea, Kim et al 99 found similar rates of survival to hospital discharge among patients with OHCA with prolonged conventional CPR compared with patients who received VA-ECMO (19% [86 of 444] versus 16% [9 of 55] , respectively). However, propensity score matching of patients who received ≥21 minutes of CPR duration showed neurological outcomes at 3 months to be more favorable with VA-ECMO than with conventional CPR (15% versus 8%). In an observational study, Maekawa et al 97 analyzed data from 162 adult Japanese patients with witnessed OHCA of presumed cardiac origin who had undergone CPR for >20 minutes before receipt of VA-ECMO. Survival to discharge was 32% (17 of 53) with VA-ECMO and 6% (7 of 109) with conventional CPR. Matched propensity analysis showed significantly higher neurologically intact survival at 3 months with VA-ECMO compared with conventional CPR (29% versus 8%; P=0.018). In the SAVE-J trial (Study of Advanced Cardiac Life Support for Ventricular Fibrillation With Extracorporeal Circulation in Japan), a prospective observational study of patients with OHCA with VF/pVT performed in Japan over a 3-year period, Sakamoto et al 25 compared patients admitted to 26 hospitals providing VA-ECMO with those admitted to 20 hospitals that did not provide VA-ECMO. In per-protocol analysis, overall 1-month survival was 29% (68 of 234) with VA-ECMO versus 6% (9 of 159) without VA-EMCO. CPC scores of 1 or 2 were achieved at 1 month in 14% (32 of 234) of patients who received VA-ECMO versus 2% (3 of 159) of those without VA-ECMO (P<0.0001) and at 6 months in 12% (29 of 234) versus 3% (5 of 159), respectively (P=0.002). In Austria, Schober et al 103 found that functionally favorable survival was 14% with VA-ECMO and 6% with conventional CPR.
Several studies have compared the potential impact of VA-ECMO between patients with refractory VF/pVT and those with nonshockable rhythms. Leick et al 104 found that 30-day survival was 38% in ECMO recipients who presented with VF/pVT and 35% in patients presenting with nonshockable rhythms. The door-to-VA-ECMO initiation time was the only significant and independent predictor of 30-day mortality. In Denmark, Fjølner et al 105 found that in patients admitted with witnessed, refractory, normothermic OHCA treated with VA-ECMO, 33% survived to hospital discharge, all with CPC 1 or 2. Survival to hospital discharge was 56% in patients with VF/pVT as the initial rhythm and 17% in patients presenting with PEA or asystole. In patients with refractory OHCA who received VA-ECMO in Lyon, France, Pozzi et al 26 found that survival to discharge was 32% (6 of 19) among those with VF/pVT and 0% (0 of 49) in patients with nonshockable rhythms (P<0.001). In a study in Paris by Lamhaut et al, 106 although overall survival in patients with refractory OHCA and VA-ECMO was only 14% (21 of 156), early field application of VA-ECMO within 60 minutes after a 9-1-1 call and careful selection of patients improved survival from 8% to 29%. Failure to subsequently perform CAG was the strongest predictor of mortality (OR, 7.1), and only patients presenting with VF/pVT ultimately survived. In 62 consecutive adult patients treated with the Minnesota Refractory VF/pVT Protocol, Yannopoulos et al 7 reported that 45% (28 of 62) of patients were discharged alive and 42% (26 of 62) were discharged with functionally favorable survival (CPC 1 or 2), all of which were functionally intact (CPC 1) at 3 months. Table 8 is a summary of the published series as of today.
The Advanced Reperfusion Strategies for Refractory Cardiac Arrest (2018-2023)
The National Institutes of Health has funded a definitive randomized trial for extracorporeal life support for refractory VF arrest. The primary end point of the ARREST trial (Advanced Reperfusion Strategies for Refractory Cardiac Arrest) is survival to hospital discharge with a modified Rankin Scale score ≤3. Secondary end points include survival at 6 months and cost per life saved. The study is powered to detect an absolute survival difference of 25% (15% versus 40%).
Importance of Quality of CPR
For patients who are treated for refractory OHCA, the inability to achieve ROSC and the continuation of a lowflow state impose a significant ischemic burden, worsening the initial injuries to vital organs. Several studies that have emerged from the Resuscitation Outcomes Consortium have confirmed the importance of maintaining optimal parameters for chest compression rate and depth and minimizing pauses in compressions on survival outcomes. Although randomized trials to date have not shown a significant benefit of mechanical over manual CPR in OHCA, mechanical CPR may be of benefit when transport from field to hospital is required during ongoing CPR to maintain quality compressions and to better ensure crew safety.
The Effect of Time in Prolonged Resuscitation Attempts: Evidence of a Golden Hour of Response
The ability to achieve ROSC with modern CPR declines sharply after the first 10 to 15 minutes of a resuscitation attempt, with 80% of survivors achieving ROSC before 15 minutes of resuscitative efforts. Within 30 minutes after the start of resuscitative efforts, 95% of survivors have achieved ROSC. [17] [18] [19] These data have been used to support termination of traditional resuscitative efforts, often ≈30 minutes. 107, 108 Conversely, programs using VA-ECMO support have now demonstrated significant survival in patients receiving 50 to 60 minutes of resuscitative efforts. Patients who achieve ROSC either spontaneously or with ECMO support within 50 to 60 minutes after the 9-1-1 call appear to have higher survival rates compared with patients who require >60 minutes of CPR with or without the addition of VA-ECMO. 7, 106, 109 Therefore, efforts to facilitate earlier VA-ECMO implementation are justified, requiring consideration of system reorganization to minimize low-flow (CPR) time.
Multisystemic Injury and Complexity of Postarrest Care
Although VA-ECMO provides a very promising new intervention for OHCA, full patient recovery requires both careful selection of possible candidates and a supporting system of care after the intervention. Odds of survival after cardiac arrest increase in hospitals that have a full complement of cardiovascular interventional capabilities, even when patients do not require these specific interventions. 110, 111 This observation suggests that the culture of care itself plays an important role in outcome and differs between sites. It also suggests that greater experience improves care for patients with acute cardiovascular collapse.
Postcardiac arrest intensive care must address multisystem organ failure. 112 The most common cause of death after reversal of cardiac arrest remains early withdrawal of life-sustaining therapy because of pre- sumed poor neurological prognosis. 110 Accurate neurological prognostication is not possible before 72 hours from cardiac arrest and likely requires longer periods of support and observation before such a determination is made. This remains an area of ongoing research. Neurocritical care expertise can be essential to prevent premature withdrawal of life-sustaining treatment for patients with potential for recovery. 113 Every organ system is affected by ischemia/reperfusion. 114 Multidisciplinary critical care, including access to comprehensive medical and surgical support services for all organ systems, may be necessary for any postarrest patient. Additional neuropsychological resources and rehabilitation services are also essential to sustain the survival gains that are achieved early with aggressive ECPR-based programs.
CONCLUSIONS
CAD is a common substrate, and its severity is a potential trigger for OHCA, especially in the case of shockable rhythms. Patients with VF/pVT OHCA should be considered at the highest severity of a continuum of acute coronary syndromes. Patients with VF/pVT have a significant burden of CAD: acute, chronic, or acute on chronic (Figure 8 ).
Current guidelines recommend early CAG and reperfusion for postarrest patients manifesting ST-segment elevation after ROSC is achieved. However, because of a lack of conclusive randomized data and ongoing perceived clinical equipoise, there is no consensus guideline on the use of CAG and coronary revascularization in patients without ST-segment elevation on ECG. Multiple randomized trials addressing this question are underway. Until their completion, there is a significant body of observational studies that address the role of the CCL in this population.
The current evidence suggests that early access to the CCL in patients resuscitated from VF/pVT cardiac arrest is associated with 2-to 3-fold higher functionally favorable survival rates than more conservative approaches of late or no access to the CCL. This body of evidence, with potential for unmeasured selection bias, suggests that patients resuscitated from OHCA, especially those with presenting shockable rhythms, should be considered for early CAG, identification of reversible causes, and revascularization when indicated.
The burden of complex CAD appears even higher in patients with refractory VF/pVT OHCA. The emergence of advanced perfusion/reperfusion strategies and early deployment of VA-ECMO and PCI when needed have shown promising results and have been associated with a 2-to 4-fold (8%-15% to 30%-45%) increase in survival in observational studies. Expansion of this approach is likely to occur in the future. Randomized trials are necessary to inform this expansion and to develop best practices to maximize the efficiency of care. The ARREST trial will address survival and cost per life saved in the United States, but results will be not available until 2023. On the basis of the available evidence, healthcare systems planning to initiate extracorporeal life support-based resuscitation for refractory OHCA should implement system-structural protocols that target a 9-1-1 call to VA-ECMO support interval of <60 minutes. They should also provide multidisciplinary postresuscitation critical care, including comprehensive medical and surgical support services. This will be critical for the effective expansion of extracorporeal life support programs.
The effect of early CCL access in nonshockable rhythms remains undefined.
PCI, mechanical circulatory support, and comprehensive postresuscitation care may provide substantial benefit. However, they are also resource intensive, requiring careful consideration. Furthermore, efforts should be undertaken with an understanding of the resource requirements to fully optimize the entire chain of survival.
ARTICLE INFORMATION
The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.
This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on August 3, 2018, and the American Heart Association Executive Committee on September 17, 2018. A copy of the document is available at http://professional.heart.org/statements by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@ wolterskluwer.com.
The American Heart Association requests that this document be cited as follows: Yannopoulos D, Bartos JA, Aufderheide TP, Callaway CW, Deo R, Garcia S, Halperin HR, Kern KB, Kudenchuk PJ, Neumar RW, Raveendran G; on behalf of the American Heart Association Emergency Cardiovascular Care Committee. The evolving role of the cardiac catheterization laboratory in the management of patients with out-of-hospital cardiac arrest: a scientific statement from the American Heart Association. Circulation. 2019;139:e530-e552. doi: 10.1161/CIR.0000000000000630.
The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://professional.heart.org/statements. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."
Permissions: Multiple copies, modification, alteration, enhancement, and/ or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at https://www.heart.org/permissions. A link to the "Copyright Permissions Request Form" appears in the second paragraph (https://www. heart.org/en/about-us/statements-and-policies/copyright-request-form). 
Disclosures
